Additionally, 3-Hydroxy-3-methylglutaryl-CoA reductase (HMGCR), a central enzyme in cholesterol biosynthesis targeted by statins, emerged as a leading candidate in a genome-wide CRISPR screening aimed at identifying TGF-β-induced drivers of liver fibrosis in HSCs (Yu et al., 2022). This evidence concerns the gene HMGCR and Hepatic fibrosis.